Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.

NCT05126888 is registered in ClinicalTrials.gov with Neurothera Labs Inc. as lead sponsor.

NCT NCT05126888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.
Lead sponsor
Neurothera Labs Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
February 29, 2028
Enrollment
164 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tourette syndrome